1. The Long Path to Diagnosis Is an Ecosystem Challenge
Biopharma organizations frequently run HCP marketing and patient engagement as separate initiatives, often splitting them between different agency partners with unconnected metrics. In rare disease, that division prolongs the diagnostic odyssey.
Primary care doctors and general specialists might encounter an ultra-rare condition once or twice across their careers. As a result, early symptoms are easily overlooked or attributed to common illnesses. Meanwhile, patients and caregivers spend years visiting multiple clinics without the clinical terminology needed to prompt the right tests.
During a panel on re-engineering HCP strategy moderated by Health Union’s Julia Tewksbury, commercial leaders Lindsey Chamorro of Alexion and Alex Crujeiras of Takeda examined this exact friction point. They highlighted how front-line physicians often work outside sales representative coverage and require targeted educational support to spot clinical triggers earlier.
The Room’s Takeaway: Brand teams must build an integrated plan where HCP and patient efforts support one another at specific moments of friction. Non-personal promotion and targeted clinical triggers can help front-line physicians spot early symptom patterns. At the same time, community-tested discussion guides help patients make the most of limited exam-room time.
2. Brands Must Earn the Right to Talk About Products
During the patient leader panel moderated by Health Union’s Julie Croner, advocates Erin Poyant (ATTR amyloidosis) and Dima Hendricks (sickle cell) delivered a direct message to brand teams: rare communities notice when pharmaceutical companies only appear around an FDA approval date.
Trust in this market comes from sustained commitment rather than promotional campaigns.
The Room’s Takeaway: Life sciences companies need to show up for communities well ahead of commercial launch and remain engaged long after a therapy reaches market. That commitment involves supporting peer connection networks, caregiver education, and disease-state awareness without immediate sales goals attached. As several participants noted during the DTC roundtables, guidance must come from the community itself rather than a corporate brief.
3. Bridge the Exam Room with a Shared Vocabulary
An audience poll during the patient panel revealed that rare disease patients frequently enter appointments knowing more about their specific disease nuances and clinical trials than the doctor sitting in front of them.
This knowledge imbalance often introduces friction or hesitation during appointments. As Croner, Poyant, and Hendricks discussed, patients who have spent months researching genetic markers or symptoms often struggle to communicate those findings clearly and concisely in a brief 15-minute consultation.
The Room’s Takeaway: Commercial teams should help patients and physicians hold more productive conversations. Rather than distributing standard promotional materials, brands should partner with patient leaders to build discussion tools that connect everyday lived experiences to specific clinical terms. When both parties use common language, referrals to specialized providers, diagnostic and treatment centers happen much faster.
4. Commercial Measurement Must Match Rare Timelines
Standard brand performance metrics rely on short attribution windows, monthly prescription counts, and rapid digital conversions. When the diagnostic journey takes three to seven years, relying on short-term consumer marketing metrics creates unrealistic expectations.
The opening keynote covered how investors look closely at early market building, disease awareness, and patient-finding capabilities because these foundational efforts directly de-risk launch trajectories over the long run.
The Room’s Takeaway: Commercial leads and analytics teams must adopt measurement frameworks tailored to rare disease realities:
- Extended Attribution Windows: Expanding look-back and evaluation timelines to capture prolonged diagnostic paths.
- Longitudinal and Referral Tracking: Monitoring shifts in clinical referral pathways, genetic testing adoption, and specialist handoffs over multi-quarter periods.
- Engagement Depth Over Broad Reach: Tracking meaningful community participation, advocacy alignment, and qualitative feedback rather than focusing on raw impressions.
5. Modernizing the Tactics: Connected TV and Broader Clinical Networks
Afternoon working sessions and an executive panel featuring Olivier Chateau, Co-founder and CEO of Health Union, alongside Robert Ehrlich, Chairman and CEO of DTC Perspectives, and Jim Potter, Executive Director of 4As Health, addressed how emerging channels and media formats fit into ultra-niche disease states:
- Connected TV (CTV) for Precision: Mass broadcast television rarely makes sense for conditions affecting a few thousand individuals nationwide, but addressable CTV allows brands to reach targeted households efficiently. Teams must manage this format carefully, balancing the evolving FDA risk-disclosure standards and stricter health data privacy regulations.
- Expanding Physician Networks: Participants in the HCP roundtables pointed out that traditional Key Opinion Leader (KOL) circles in rare conditions can become repetitive. Leading brand teams are adding community-based clinicians and patient leaders into their advisory boards, bringing fresh perspectives into commercial planning.
Looking Ahead to DTC National 2027
Discussions in Boston demonstrated how much rare disease and niche oncology brand teams value practical, collaborative discussions focused on real patient outcomes.
To continue this dialogue, Health Union and DTC Perspectives are expanding their partnership into 2027 by introducing an official Rare Disease Workshop and Awards Ceremony at the annual DTC National Conference.
Registration details, agenda highlights, and award submission guidelines will be announced in the coming months as both organizations work to advance rare disease marketing together.
To review the roundtable notes or learn more about Health Union’s rare disease programs, reach out to our team at pr@health-union.com.
